Citius Pharma Overview

  • Founded

  • 2007

Founded
  • Status

  • Public

  • Employees

  • 15

Employees
  • Stock Symbol

  • CTXR

Stock Symbol
  • Investments

  • 3

  • Share Price

  • $1.17

  • (As of Friday Closing)

Citius Pharma General Information

Description

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.

Contact Information

Website
www.citiuspharma.com
Ownership Status
Publicly Held
Financing Status
Formerly Angel backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 11 Commerce Drive
  • First Floor
  • Cranford, NJ 07016
  • United States
+1 (908) 000-0000

Citius Pharma Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Citius Pharma Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.17 $1.19 $0.83 - $2.35 $174M 146M 1.14M -$0.19

Citius Pharma Financials Summary

In Thousands,
USD 		TTM 31-Mar-2022 FY 2021 30-Sep-2021 FY 2020 30-Sep-2020 FY 2019 30-Sep-2019
EV 197,385 182,337 50,567 17,506
Revenue 0 0 0 0
EBITDA (27,430) (23,141) (17,448) (15,597)
Net Income (27,571) (23,054) (17,548) (15,562)
Total Assets 127,786 142,429 43,774 36,746
Total Debt 769 855 1,352 173
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Citius Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Citius Pharma‘s full profile, request access.

Request a free trial

Citius Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique
Pharmaceuticals
Cranford, NJ
15 As of 2021
000.00
000000000 000.00

000000

iscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim ven
000000000000000
Ardsley, NY
000 As of 0000
00000
0.00 0000-00-00
000000&0

000000

citation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehend
0000 000000000
San Francisco, CA
0 As of 0000
0000
000000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Citius Pharma Competitors (47)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Acorda Therapeutics Formerly VC-backed Ardsley, NY 000 00000 000000&0
000000 Formerly VC-backed San Francisco, CA 0 0000 000000000000 0000
00000000 Corporation Berkeley Heights, NJ 00 000.00 000000&0
00000000 000000000 Corporation Watertown, MA 000 00000 000000000 00000
0000000 0000000000 Formerly PE-Backed Solana Beach, CA 00 000000&0
You’re viewing 5 of 47 competitors. Get the full list »

Citius Pharma Executive Team (9)

Name Title Board Seat Contact Info
Jaime Bartushak Chief Financial Officer & Chief Business Officer
Myron Czuczman Chief Medical Officer & Executive Vice President
Gary Talarico Executive Vice President, Operations
Andrew Scott Vice President, Corporate Development and Investor Relations
Ilanit Allen Vice President, Investor Relations
You’re viewing 5 of 9 executive team members. Get the full list »

Citius Pharma Board Members (8)

Name Representing Role Since
Carol Webb Citius Pharma Board Member 000 0000
Eugene Holuka MD Citius Pharma Board Member 000 0000
Howard Safir Citius Pharma Board Member 000 0000
Leonard Mazur Self Chief Executive Officer & Chairman 000 0000
Myron Holubiak Citius Pharma Board Member & Vice Chairman 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Citius Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Citius Pharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Citius Pharma‘s full profile, request access.

Request a free trial

Citius Pharma Investments & Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00. 00000 (00 07-Sep-2021 000000000 0000 Buildings and Property 00000 000
0000000-00000 04-Apr-2016 0000000000 Biotechnology 0000000 0
Trail One 12-Sep-2014 Merger/Acquisition 00.000 Automotive
To view Citius Pharma’s complete investments and acquisitions history, request access »